News summary

Resolution’s engineered immune cells show early liver promise

Source: Longevity Technology • Published: 16 Nov 2026, 12:51

Summarized by Masters of Longevity from Longevity Technology.

Early interim data showed clinical benefit signals in advanced liver disease patients.

Resolution’s engineered immune cells show early liver promise
Key Takeaways
  • Nine patients were included in the interim readout.
  • Engineered autologous macrophages are aimed at regeneration and antifibrosis.
  • The findings are preliminary and have not established causal efficacy.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickWhat Changes in the Human Hippocampus with Age?A study of 40 postmortem brains maps a midlife shift in immune cells and a wider loss of cellular and genome organisation—but it does not show how to prevent cognitive decline.MoL PickNucleotides and Longevity: Is the Evidence Ready?They help build DNA and keep cells working. Early human studies make nucleotide supplements interesting—but leave important questions about healthy ageing unanswered. Yet.MoL PickCreatine and Cancer: Why New Mouse Studies Point in Opposite DirectionsCreatine strengthened antitumour immune cells in one mouse study—and promoted metastasis through platelets in another. The apparent contradiction reveals why neither result is a supplement recommendation.